^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Abstract 2196: SRF231, a fully human CD47 antibody, potentiates the effects of opsonizing antibodies and cytotoxic chemotherapies in preclinical cancer models

Published date:
05/15/2020
Excerpt:
In vivo, SRF231 monotherapy induced anti-tumor activity and significantly increased median survival time in preclinical EGFR mutant (H1975) and EGFR wildtype (A549) NSCLC xenograft models. 
DOI:
10.1158/1538-7445.AM2020-2196